Drug intelligence / Profile preview

Tiaochang Xiaoyan tablets

Development stage: Unknown
Lead developer: The Second Affiliated Hospital of Guangzhou University of Chinese Medicine
Administration: Oral

Overview

Tiaochang Xiaoyan tablets is a Traditional Chinese Medicine (TCM) preparation developed by The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (also known as the Guangdong Provincial Hospital of Chinese Medicine). It is formulated to treat ulcerative colitis by "regulating the intestines and diminishing inflammation," a therapeutic approach aligned with clearing damp-heat in the large intestine. The preparation is currently being investigated in clinical trials, specifically in combination with standard-of-care mesalamine, for its efficacy and safety in patients with mild to moderate active ulcerative colitis.

Other names: Tiaochang Xiaoyan pianTiaochang Xiaoyan tablets

Beyond the preview

Go deeper on Tiaochang Xiaoyan tablets.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tiaochang Xiaoyan tablets.

Explore the full profile